Member of Senior Leadership Team and reporting to CEO.

CEO of SSI Diagnostica Holding A/S - includes SSI Diagnostica A/S and CTK Biotech, Inc.

- Global commercial responsible (Sales, Marketing, Business Development) - Member in Corporate Management team.- Building and expanding SSI Diagnostica A/S global sales performance. - Expanding the base of very motivated, highly skilled and very passionate colleagues. SSI Diagnostica A/S is a very well positioned diagnostic company with high quality products targeting microbiology laboratories (hospital & industry), life science industry and general practise doctors.

RESPONSIBILITIES: - Regional Vice President responsible for region: Russia, CIS countries, Belarus, Slovakia, Croatia, Serbia, Slovenia, Malta and the Baltics. Reporting to SVP Joao Carlos Rocha.- Optimise current and new products sales and profits. -140 FTE in total team, affiliate offices and country managers directly reporting (excl. distributor in CIS, Belarus and Malta)RESULTS: - Analysis, define and implement new Go to market strategy for new product launches, including adjustments in organizational setup. - Sign and implement co-promotion agreement with R Pharm in Russia. - High sales and profits of Cipralex and Lundbeck mature products. - Launch Brintellix, Abilify Maintena, Selincro. Brintellix in the top 3 of global Brintellix launches, with 0,70 vol. MS% 3 months after launch.

RESPONSIBILITIES- General Manager and responsible for establishing New Region in Lundbeck. Countries: Costa Rica, Panama, Guatemala, Dominican Republic, Nicaragua, el Salvador, Honduras, Caribbean (Jamaica, Curacao, Aruba), Equador. 11 markets with 82 million inhabitants. Reporting to RVP Alberto Weder.- Build up new markets; relaunch current products and prepare for launch of new products. - 27 FTE in total team. Regional office in Panama City. RESULTS- Established successfully Lundbeck America Central SA, from nothing to a high performing company increasing sales and profits and getting ready for new product launches. - Analysis, define and implement optimal market by market distributor setup and sales channels. - Established a low cost and flexible warehouse and supply chain setup with base in Colon Free Zone with Colon Import & Export SA. - Strong increase in market shares, sales and profits of Lexapro/Cipralex and mature products. - Employee satisfaction survey (ESS 2013) showed that Lundbeck America Central employees reported index 89 for satisfaction and motivation. Same measure was 82 for Latin America as a group and 74 for H. Lundbeck A/S globally.

RESPONSIBLE- Head of Global Strategic Marketing Established and New Products. Reporting to EVP Stig Løkke Pedersen. - Develop go to market strategies and launch plans for Lundbeck new products (Brintellix (Major Depression), Selincro (Alcohol reduction), Desmoteplase (Ischemic Stroke). - Cross organizational collaboration with R&D to design phase IIIB and IV clinical study programmes.- Optimize global sales of established products:Ebixa (Alzhiemers), Azilect (Parkinson) - joint venture with Teva Pharmaceuticals, Circadin (Sleep) RESULTS:- Signifincant sales growth of Cipralex/Lexapro, Ebixa, Azilect, reported by IMS Global sales data. - Define strategic direction and launch platform for Brintellix- In licensing and commercial launch of Sycrets/Saphris. - Establish new Corporate Payer and Market Access department. - Establish Medical Affairs division.

RESPONSIBILITIES- Head of Strategic Marketing Established Products- Responsible for optimising global sales and profits of Cipralex, Lexapro (USA), Ebixa, Azilect, Circadin. - 40 employees in own organisation; 4 product/brand teams, 1 congress and 1 sales excellence team, cross organisational project management from R&D, Regulatory, Patent, Finance, Supply, etc. RESULTS- Cipralex/Lexapro obtained value market leadership with more than 3 billion USD global sales (Launched 2002) - Significant sales growth of Cipralex/Lexapro, Ebixa and Azilect reported by IMS Global Sales. - Launch of "I CAN" - internet based patient compliance system.

RESPONSIBILITIES- Team Leader for Cipralex/Lexapro global marketing. - Objective: Optimise Cipralex/Lexapro global sales and profits via defining, communicating, implementing global commercial strategies, tactics and life cycle management. - Cross organisational collaboration in headquarter and in country affiliates to ensure speed and maximum effect of defined commercial strategies and tactics. RESULTS- Significant sales growth of Cipralex/Lexapro, reported by IMS Global Sales. - International launch of the "Allosteric mechanism" campaign for Cipralex. - Developed international research field with allosteric pharmacology to support the communication of Cipralex unique mode of pharmacological action. - Established lean process for execution of congress and event planning and implementation.

RESPONSIBILITIES- Senior Project Director for Cipralex/Lexapro in R&D Project Management organisation.- Teamleader for cross organisational teams (Clinical Research, Regulatory, Patent, Sales, Marketing, Supply, SMC, Finance, Business Development). - Reported directly to H. Lundbeck CEO, Claus Bræstrup. - Optimise Cipralex/Lexapro global long term sales and profit via developing and implementing life cycle management strategies and tactics. RESULTS- European Regulatory agencies approval of Cipralex/Lexapro allosteric mechanism of action, which explains Cipralex faster and strong efficacy; major competitive advantage => estimated to have increased Cipralex/Lexapro European and International markets peak sales by 35-40%. - First Cipralex patent court case and establishment of European lawyer network prepared to defend a potential patent infringement of Cipralex. - Decide, develop and launch new drops formulation for the Italian market; - 35% of sales within N6A in Italy is drops formulations.

RESPONSIBILITIES- Director for Business Development (Geographic) and Alliance Management- Develop strategic recommendations to H. Lundbeck A/S management group for where and how to expand Lundbeck geographic reach. - Responsible for optimising Lundbeck partnerships; Forest Laboratories (Lexapro), Merz (Ebixa), Teva (Azilect), Cephalon (CEP 1347). - Evaluate new business opportunities and provide recommendations to Lundbeck management group. RESULTS- Negotiate, close and implement Gaboxadol (sleep) partnership agreement with Merck Sharp Dome (MSD), USA. (In collaboration with head of Corporate Business Development Ole Vahlgren). - The Gaboxadol partnership agreement was the biggest in Lundbeck history; 400 mil. DKK in down payment and milestone payments of 1.200 mil. DKK, as well as strategic and tactical entry to the USA market for Lundbeck. - Develop Lundbeck USA strategy and implementation plan for own Lundbeck sales and marketing organisation in the USA (Greenfield or Acquisition)- Identify, evaluate and negotiate with several USA acquisition candidates.

RESPONSIBILITIES- Business development manager with responsibility for Lundbeck geographic expansion on the American continent (Latin America and USA). - Evaluate new markets and new product opportunities to accelerate growth. Provide recommendation to SVP and Lundbeck Corporate management group. - Close collaboration with Lundbeck Regional SVP Americas, Ole Chrintz. RESULTS- Instrumental in analysing, defining strategy, implementing and establishing Lundbeck in Brazil, Argentina and Chile. - Co-promotion partnership agreement with Abbott Laboratories to launch Lexapro in all Latin American markets March 2003. - Instrumental in analysing, defining and recommending the strategy for how to establish Lundbeck in the USA. Amongst other things search, evaluation and negotiate with USA specialty company.

 Training of 15 inexperienced combat soldiers  Management and training exercises with this combat group Guarding the Danish Queen – management of the guards.